Myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin ATPase activity

Circulation: Heart Failure

Volumn 8, Issue 4, 2015, Pages 766-775

  Bakkehaug, Jens Petter ^a   Kildal, Anders Benjamin ^a,b   Engstad, Erik Torgersen ^a   Boardman, Neoma ^a   Næsheim, Torvind ^a   Rønning, Leif ^a   Aasum, Ellen ^a   Larsen, Terje Steinar ^a   Myrmel, Truls ^a,b   How, Ole Jakob ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Contractility; Heart failure; Inotropic agent; Myocardial metabolism; Omecamtiv mecarbil; Oxygen consumption

Indexed keywords

MYOSIN ADENOSINE TRIPHOSPHATASE; OMECAMTIV MECARBIL; CARDIOTONIC AGENT; ENZYME ACTIVATOR; MYOSIN; UREA;

ACUTE HEART FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA PRESSURE; ARTICLE; BASAL METABOLIC RATE; CONTINUOUS INFUSION; CONTROLLED STUDY; ENERGY CONSUMPTION; EX VIVO STUDY; GLUCOSE OXIDATION; HEART; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; LUNG ARTERY PRESSURE; LUNG CIRCULATION; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; PERFUSION PRESSURE; PIG; PRIORITY JOURNAL; REPERFUSION INJURY; ANALOGS AND DERIVATIVES; ANIMAL; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; HEART CONTRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART STROKE VOLUME; METABOLISM; MOUSE; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY;

ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVATORS; FEMALE; HEART FAILURE; MALE; MICE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOSINS; OXYGEN CONSUMPTION; STROKE VOLUME; SUS SCROFA; UREA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84942920424     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.002152     Document Type: Article

References (24)

1. Morgan BP, Muci A, Lu PP, Qian X, Tochimoto T, Smith WW, Garard M, Kraynack E, Collibee S, Suehiro I, Tomasi A, Valdez SC, Wang W, Jiang H, Hartman J, Rodriguez HM, Kawas R, Sylvester S, Elias KA, Godinez G, Lee K, Anderson R, Sueoka S, Xu D, Wang Z, Djordjevic N, Malik FI, Morgans DJ Jr. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. ACS Med Chem Lett. 2010;1:472-477. doi: 10.1021/ml100138q.
2. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331:1439-1443. doi: 10.1126/science.1200113.
3. Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011;378:667-675. doi: 10.1016/S0140-6736(11)61219-1.
4. Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarza P, Morgans DJ, Vatner SF. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail. 2010;3:522-527. doi: 10.1161/CIRCHEARTFAILURE.109.930321.
5. Korvald C, Elvenes OP, Aghajani E, Myhre ES, Myrmel T. Postischemic mechanoenergetic inefficiency is related to contractile dysfunction and not altered metabolism. Am J Physiol Heart Circ Physiol. 2001;281:H2645-H2653.
6. Boardman N, Hafstad AD, Larsen TS, Severson DL, Aasum E. Increased O2 cost of basal metabolism and excitation-contraction coupling in hearts from type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 2009;296:H1373-H1379. doi: 10.1152/ajpheart.01264.2008.
7. Aasum E, Hafstad AD, Severson DL, Larsen TS. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes. 2003;52:434-441. doi: 10.23337/diabetes.52.2.434.
8. Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011;378:676-683. doi: 10.1016/S0140-6736(11)61126-4.
9. Palmer JW, Tandler B, Hoppel CL. Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. J Biol Chem. 1977;252:8731-8739.
10. Helak JW, Reichek N. Quantitation of human left ventricular mass and volume by two-dimensional echocardiography: in vitro anatomic validation. Circulation. 1981;63:1398-1407.
11. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol. 2000;278:H1345-H1351.
12. Sarnoff SJ, Berglund E, Welch GH, Case RB, Stainsby WN, Macruz R. Ventricular function: I. Starlings law of the heart studied by means of simultaneous right and left ventricular function curves in the dog. Circulation. 1954;9:706-718.
13. Suga H. Ventricular energetics. Physiol Rev. 1990;70:247-277.
14. Domenech RJ, Hoffmann JIE, Noble MIM, Saunders KB, Henson JR, Subijanto S. Total and regional coronary blood flow measured by radioactive microspheres in conscious and anestesized dogs. Circ Res. 1969;25;581-596.
15. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497-509.
16. Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest. 1987;79:359-366. doi: 10.1172/JCI112820.
17. Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andreassen M, Larsen TS. Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-activator. Am J Physiol Hear Circ Physiol. 2002;28:949-957. doi: 10.1152/ajpheart.00226.2001.
18. Mller S, How OJ, Jakobsen , Hermansen SE, Rsner A, Stenberg TA, Myrmel T. Oxygen-wasting effect of inotropy: is there a need for a new evaluation? An experimental large-animal study using dobutamine and levosimendan. Circ Heart Fail. 2010;3:277-285. doi: 10.1161/CIRCHEARTFAILURE.109.865519.
19. Strauer BE. Myocardial oxygen consumption in chronic heart disease: role of wall stress, hypertrophy and coronary reserve. Am J Cardiol. 1979;44:730-740.
20. Anderson RL, Sueoka SH, Rodriguez HM, Lee KH, Kawas R, Morgan BP, Sakowicz R, Morgans DJ Jr, Malik F, Elias KA. In vitro and in vivo efficacy of the cardiac myosin activator CK-1827452. Mol Bio Cell. 2005;16 (Abstract No. 1728)
21. Opie LH. Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction. Relation to myocardial ischemia and infarct size. Am J Cardiol. 1975;36:938-953.
22. Gustafsson AB, Gottlieb RA. Heart mitochondria: gates of life and death. Cardiovasc Res. 2008;77:334-343. doi: 10.1093/cvr/cvm005.
23. Gibbs CL, Loiselle DS. Cardiac basal metabolism. Jpn J Physiol. 2001;51:399-426. doi: org/10.2170/jjphysiol.51.339.
24. Ebus JP, Stienen GJ. Origin of concurrent ATPase activities in skinned cardiac trabeculae from rat. J Physiol. 1996;492 (Pt 3):675-687.